Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of congestive heart failure

a congestive heart failure and patient technology, applied in the field of treating patients with congestive heart failure, can solve the problems of insufficient current therapy for heart failure, inconsistent inability to relieve symptoms in more than 60% of heart failure patients, etc., to improve cardiac function, reduce peripheral vascular resistance, and increase ventricular contractility

Inactive Publication Date: 2005-08-04
GENENTECH INC
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

GH treatment enhances cardiac function by increasing ventricular contractility and reducing peripheral vascular resistance in patients with congestive heart failure, providing a more effective alternative to existing therapies.

Problems solved by technology

Current therapy for heart failure is insufficient.
Although angiotensin converting enzyme (ACE) inhibitors have been shown to have beneficial effects in patients with heart failure, they appear consistently unable to relieve symptoms in more than 60% of heart failure patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of congestive heart failure
  • Treatment of congestive heart failure
  • Treatment of congestive heart failure

Examples

Experimental program
Comparison scheme
Effect test

examples

Use of GH to Treat Congestive Heart Failure

Introduction

[0075] The goal of this study was to examine the cardiac effects of human GH treatment in an animal model of congestive heart failure.

Methods

[0076] Male Sprague-Dawley (SD) rats (Charles River Breeding Laboratories, Inc., eight weeks of age) were acclimated to the facility for at least 1 week before surgery. Rats were fed a pelleted rat chow and water ad libitum and housed in a light and temperature controlled room.

Coronary Arterial Ligation

[0077] Myocardial infarction was produced by left coronary arterial ligation as described previously. Greenen, D. L. er al., J. Appl. Physiol. 63: 92-96 (1987); Buttrick, P. et al., Am. J. Physiol. 260: 11473-11479 (1991). The rats were anesthetized with sodium pentobarbital (60) mg / kg, ip), intubated via tracheotomy, and ventilated by a respirator (Harvard Apparatus Model 683). After a left-sided thoracotomy, the left coronary artery was ligated approximately 2 mm from its origin with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
molecular weightaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.

Description

RELATED APPLICATIONS [0001] This is a non-provisional continuation application of co-pending application(s) Ser. No. 10 / 848,814 filed on May 18, 2004, which is a continuation of Ser. No. 10 / 623,129 filed on Jul. 18, 2003, which is a continuation of Ser. No. 10 / 288,254 filed Nov. 4, 2002, which is a continuation of Ser. No. 10 / 045,622 filed on Oct. 24, 2001, which is a continuation of Ser. No. 09 / 724,787 filed on Nov. 28, 2000, which is a continuation of Ser. No. 09 / 550,736, filed Apr. 17, 2000, which is a continuation of Ser. No. 09 / 302,924, filed Apr. 30, 1999, which is a continuation of application Ser. No. 08 / 228,548, filed Apr. 15, 1994, now U.S. Pat. No. 5,935,924 which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC § 120.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] This invention relates to the field of treating patients having congestive heart failure with growth hormone (GH). [0004] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/27A61P9/00A61P9/08A61P9/10
CPCA61K38/27A61P9/00A61P9/08A61P9/10
Inventor BUNTING, STUARTCLARK, ROSSGILLETT, NANCYJIN, HONGKUIYANG, RENHUI
Owner GENENTECH INC